他汀类药物和先兆子痫:来自阿根廷高血压学会妇女高血压工作组的最新进展。

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
A.M. Ghelfi , G. Miranda , L.S. Voto , J.M. Zilberman , M.A. Del Sueldo , F. Waisman , M. Baroni , M.V. Ferretti , J.P. Moran , A. Corrales-Barboza , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M.L. Baiche , A.M. Delucchi , P.D. Rodríguez , N.F. Renna
{"title":"他汀类药物和先兆子痫:来自阿根廷高血压学会妇女高血压工作组的最新进展。","authors":"A.M. Ghelfi ,&nbsp;G. Miranda ,&nbsp;L.S. Voto ,&nbsp;J.M. Zilberman ,&nbsp;M.A. Del Sueldo ,&nbsp;F. Waisman ,&nbsp;M. Baroni ,&nbsp;M.V. Ferretti ,&nbsp;J.P. Moran ,&nbsp;A. Corrales-Barboza ,&nbsp;R. Mondino ,&nbsp;M.P. Pérez ,&nbsp;P.G. Irusta ,&nbsp;L. Meccia ,&nbsp;E. Martínez Marissi ,&nbsp;M.L. Baiche ,&nbsp;A.M. Delucchi ,&nbsp;P.D. Rodríguez ,&nbsp;N.F. Renna","doi":"10.1016/j.hipert.2025.03.001","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertensive disorders of pregnancy (HDP) affect 5–10% of pregnancies. Preeclampsia (PE) is a severe complication of HDP, associated with high maternal, fetal, and neonatal morbidity and mortality. The pathophysiology of PE involves endothelial dysfunction, vasoconstriction, and impaired placental perfusion, leading to systemic inflammation and multi-organ dysfunction. It has been suggested that statins, traditionally contraindicated during pregnancy, could play a role in this context. Some studies propose that pravastatin, a hydrophilic statin, may not have the same teratogenic effects as lipophilic statins, potentially improving maternal vascular status and significantly reducing the risk of PE. Considering this, the Working Group on Hypertension in Women of the Argentine Society of Hypertension undertook a review of the topic and its current implications.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 3","pages":"Pages 147-155"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Statins and preeclampsia: An update from the Working Group on Hypertension in Women, Argentine Society of Hypertension\",\"authors\":\"A.M. Ghelfi ,&nbsp;G. Miranda ,&nbsp;L.S. Voto ,&nbsp;J.M. Zilberman ,&nbsp;M.A. Del Sueldo ,&nbsp;F. Waisman ,&nbsp;M. Baroni ,&nbsp;M.V. Ferretti ,&nbsp;J.P. Moran ,&nbsp;A. Corrales-Barboza ,&nbsp;R. Mondino ,&nbsp;M.P. Pérez ,&nbsp;P.G. Irusta ,&nbsp;L. Meccia ,&nbsp;E. Martínez Marissi ,&nbsp;M.L. Baiche ,&nbsp;A.M. Delucchi ,&nbsp;P.D. Rodríguez ,&nbsp;N.F. Renna\",\"doi\":\"10.1016/j.hipert.2025.03.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Hypertensive disorders of pregnancy (HDP) affect 5–10% of pregnancies. Preeclampsia (PE) is a severe complication of HDP, associated with high maternal, fetal, and neonatal morbidity and mortality. The pathophysiology of PE involves endothelial dysfunction, vasoconstriction, and impaired placental perfusion, leading to systemic inflammation and multi-organ dysfunction. It has been suggested that statins, traditionally contraindicated during pregnancy, could play a role in this context. Some studies propose that pravastatin, a hydrophilic statin, may not have the same teratogenic effects as lipophilic statins, potentially improving maternal vascular status and significantly reducing the risk of PE. Considering this, the Working Group on Hypertension in Women of the Argentine Society of Hypertension undertook a review of the topic and its current implications.</div></div>\",\"PeriodicalId\":39403,\"journal\":{\"name\":\"Hipertension y Riesgo Vascular\",\"volume\":\"42 3\",\"pages\":\"Pages 147-155\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hipertension y Riesgo Vascular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1889183725000297\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183725000297","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

妊娠期高血压疾病(HDP)影响5-10%的妊娠。先兆子痫(PE)是HDP的严重并发症,与母体、胎儿和新生儿的高发病率和死亡率相关。PE的病理生理包括内皮功能障碍、血管收缩和胎盘灌注受损,导致全身炎症和多器官功能障碍。有人建议,他汀类药物,传统禁忌在怀孕期间,可能在这种情况下发挥作用。一些研究认为,亲水他汀类药物普伐他汀可能没有亲脂他汀类药物那样的致畸作用,可能会改善母体血管状况,显著降低PE的风险。考虑到这一点,阿根廷高血压学会妇女高血压问题工作组审查了该专题及其目前的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Statins and preeclampsia: An update from the Working Group on Hypertension in Women, Argentine Society of Hypertension
Hypertensive disorders of pregnancy (HDP) affect 5–10% of pregnancies. Preeclampsia (PE) is a severe complication of HDP, associated with high maternal, fetal, and neonatal morbidity and mortality. The pathophysiology of PE involves endothelial dysfunction, vasoconstriction, and impaired placental perfusion, leading to systemic inflammation and multi-organ dysfunction. It has been suggested that statins, traditionally contraindicated during pregnancy, could play a role in this context. Some studies propose that pravastatin, a hydrophilic statin, may not have the same teratogenic effects as lipophilic statins, potentially improving maternal vascular status and significantly reducing the risk of PE. Considering this, the Working Group on Hypertension in Women of the Argentine Society of Hypertension undertook a review of the topic and its current implications.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hipertension y Riesgo Vascular
Hipertension y Riesgo Vascular Medicine-Internal Medicine
CiteScore
1.70
自引率
16.70%
发文量
38
审稿时长
39 days
期刊介绍: La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信